Source: Eur Respir J 2006; 27: 895-901



Rating:

Share or cite this content

Citations should be made in the following way:
Dooms C. A., Lievens Y. N., Vansteenkiste J. F.. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 2006; 27: 895-901

Member's Comments

No comment yet.

Related content which might interest you: A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 244–259 Year: 2009 Is there any place for perioperative radiation therapy? Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Chemotherapy in nonsmall cell lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=218 Year: 2001 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Use of 2nd-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018